Pluri

Pluri ROCE

The Return on Capital Employed (ROCE) of Pluri (PLUR) as of Oct 21, 2026 is 143.04 %. In the previous year, Return on Capital Employed (ROCE) was 2,563.70 % — a change of -94.42% (lower).

ROCE

143.04 %

YoY

-94.42%

Last updated:

In 2026, Pluri's return on capital employed (ROCE) was 143.04 %, a -94.42% increase from the 2,563.70 % ROCE in the previous year.

The Pluri ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
-162.83 USD
Jan 1, 2020
-52.54 USD
Jan 1, 2021
-88.58 USD
Jan 1, 2022
-129.23 USD
Jan 1, 2023
-178.08 USD
Jan 1, 2024
-409.20 USD
Jan 1, 2025
2,563.70 USD
Jan 1, 2026
143.04 USD
The Pluri ROCE history
YEARROCEYoY
143.04 %-94.42%
2,563.70 %-726.52%
-409.20 %+129.78%
-178.08 %+37.80%
-129.23 %+45.89%
-88.58 %+68.59%
-52.54 %-67.73%
-162.83 %+37.62%
-118.33 %+27.75%
-92.62 %+51.55%
-61.11 %+40.63%
-43.46 %-3.06%
-44.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pluri Stock analysis

What does Pluri do? Pluri, Inc. develops cell therapies for critical limb ischemia, post-surgical femoral neck fracture recovery, and acute radiation syndrome. Its lead products PLX-PAD and PLX R18 utilize placental-derived stromal cells expanded through a 3D synthetic scaffold process. These adherent stromal cells are administered via standard needle and syringe for cardiovascular, orthopedic, pulmonary, and women's health indications. The company focuses on research, clinical trials, and manufacturing of cell therapeutics. The firm's PLX cells are grown in a 3D artificial environment using synthetic scaffolds, enabling scalable production of adherent stromal cells. PLX-PAD and PLX R18 are in clinical development for multiple therapeutic areas including cardiovascular, orthopedic, pulmonary, and women's health diseases. The company's operations span research, development, clinical trials, and manufacturing of cell-based treatments. Pluri, Inc. targets clinical-stage development for cell therapies with specific focus on critical limb ischemia, femoral neck fracture recovery, and acute radiation syndrome. Its products PLX-PAD and PLX R18 are designed for administration through standard medical delivery methods. The company's therapeutic portfolio covers cardiovascular, orthopedic, pulmonary, and women's health applications through its PLX cell technology platform. Pluri is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Pluri's Return on Capital Employed (ROCE)

Pluri's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Pluri's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Pluri's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Pluri’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Pluri stock

Return on Capital Employed (ROCE) of Pluri is 143.04 % in 2026.

Return on Capital Employed (ROCE) of Pluri changed from 2,563.70 % to 143.04 %, representing a -94.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Pluri since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Pluri with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Pluri

All Key Metrics — Pluri